Less Survivable Cancers

John Lamont Excerpts

Tuesday 6th January 2026 Westminster Hall

[Clive Jones]

The hon. Member makes a very good intervention. He is absolutely right that we need to ensure that this is covered in the national cancer plan. From what I am hearing, I am optimistic that it will be.

[John Lamont (Berwickshire, Roxburgh and Selkirk) (Con)]

The hon. Member is making an excellent speech. My constituent Fiona Tweedie asked me to attend this debate because she sadly lost her husband to a brain tumour last year. She asked me to flag, in relation to the national cancer strategy, the fact that it is very difficult in Scotland to access clinical trials, and if someone is based in Scotland, they cannot access English trials. Does the hon. Member agree that this needs to be a genuinely national strategy, and that it must not allow different parts of the UK to take different directions?

[Clive Jones]

The hon. Member makes a good point; we definitely need more clinical trials in this country. We have been lagging behind in the last few years, and we need them nationally, rather than just in Scotland, Wales, England or Northern Ireland. That would be advantageous for both drug companies and the people who benefit from those trials.

For many of these less survivable cancers, survival rates in the UK lag behind other countries. We can see from our international counterparts, including Australia, Belgium, Denmark and the US, that progress is achievable, and that system reforms can play a key role in driving better patient outcomes. For example, the UK is ranked 29th out of 33 countries for pancreatic cancer survival. It is fair to ask the Minister: why is the UK ranked so low? It is also fair to ask the Conservative shadow Minister, the hon. Member for Sleaford and North Hykeham (Dr Johnson): why are we ranked so low after the Conservatives’ 14 years in Government? Perhaps it is due to the challenges in how our healthcare and cancer services are organised, and our service delivery, rather than the availability of treatment options. It is vital that we learn from our international counterparts and understand what systemic changes they have made to drive progress.

The all-party parliamentary group on less survivable cancers, of which I am a member, launched an inquiry into earlier detection and faster diagnosis. During the inquiry, the APPG heard from people with lived experience—clinicians, researchers, charities and the industry—about what vital measures are needed in the national cancer plan to improve earlier detection and faster diagnosis. The APPG found that if earlier diagnosis rates were doubled, an additional 7,500 lives would be saved every year. Deaths from those cancers could quickly be reduced by 10%.

Faster diagnosis is integral to saving lives and improving outcomes for people impacted by less survivable cancers. Simply put, it enables patients to access treatment and care much quicker, increasing their chances of survival. We are currently far from achieving this: just 28% of less survivable cancers are diagnosed at stages 1 or 2, compared with 54% for all other cancers. Concerningly, brain tumours are diagnosed in emergency settings, which is closely linked to worse outcomes.

That is common for myeloma patients—an incurable blood cancer. A third of people with myeloma are diagnosed via emergency presentation. Like the delay in diagnosing less survivable cancers, this means that their cancer has progressed untreated, and the condition has become more advanced, so their ability to tolerate treatments may be seriously hampered. The APPG’s inquiry produced some recommendations for the Government that illustrate the broad range of actions needed to achieve earlier detection and faster diagnosis, from equipping GPs with better tools and rolling out targeted screening programmes to promoting greater research into innovative diagnostics.